Attorneys from firms in Dallas and Houston secured a $42 million jury verdict on patent infringement for a state university and bioengineering company against Boston Scientific Corp.

The trial in the U.S. District Court for the District of Delaware concluded with plaintiff attorneys prevailing on patent infringement claims related to a biodegradable polymer fiber drug delivery system that was incorporated into Massachusetts-based Boston Scientific’s SYNERGY branded coronary stents.